Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 1577-1590 |
| Number of pages | 14 |
| Journal | The Lancet |
| Volume | 397 |
| Issue number | 10284 |
| DOIs | |
| Publication status | Published - 24 Apr 2021 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: The Lancet, Vol. 397, No. 10284, 24.04.2021, p. 1577-1590.
Research output: Contribution to journal › Review article › Academic › peer-review
TY - JOUR
T1 - Alzheimer's disease
AU - Scheltens, Philip
AU - de Strooper, Bart
AU - Kivipelto, Miia
AU - Holstege, Henne
AU - Chételat, Gael
AU - Teunissen, Charlotte E.
AU - Cummings, Jeffrey
AU - van der Flier, Wiesje M.
N1 - Funding Information: Research at the Alzheimer Center Amsterdam is part of the neurodegeneration research programme of Amsterdam Neuroscience. The Alzheimer Centre Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc Fonds. The chair of Wiesje van der Flier is supported by the Pasman Stichting. MK and PS are recipients of the JPND-funded Euro-FINGERS project (#ZonMW 733051102). Funding Information: PS reports research support from Alzheimer Nederland, Dioraphte, Stichting VUmc Fonds, and Stichting Alzheimer & Neuropsychiatrie; is a consultant for EIP Pharma, Vivoryon, Toyama Fuji Film, AC Immune, Axon Neuroscience, GemVax, Medavante, Novartis Cardiology, and Green Valley; is co-editor-in-chief of Alzheimer's Research & Therapy; and is a part-time managing partner of the Life Science Partners Dementia Fund since Oct 1, 2020 (after acceptance of this Seminar). BDS reports research support from Janssen Pharmaceutica, European Research Council, various academic research sponsors, Methusalem Grant of the Flemish Government, Medical Research Council, Alzheimer Association (USA), Alzheimer Research UK, and Alzheimer Society (UK). BDS is a consultant for Eisai Pharmaceuticals and holds several patents ( appendix p 13 ). MK reports research support from Academy of Finland, Swedish Research Council, Joint Program of Neurodegenerative Disorders, IMI, Knut and Alice Wallenberg Foundation, Center for Innovative Medicine, Stiftelsen Stockholms Sjukhem, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Alzheimer's Research and Prevention Foundation, Alzheimerfonden, Hjärnfonden, Region Stockholm, and Leif Lundblad Foundation grants. MK is part of a guidelines development group in WHO, a Governance Committee member of the Global Council on Brain Health, and is on the advisory board for Combinostics, Roche, and Biogen. HH reports research support from ZonMw, NWO, EU-JPND, Alzheimer Nederland, and Stichting Dioraphte. GC reports research support from European Union Horizon 2020 programme, INSERM, Fondation d'entreprise MMA des Entrepreneurs du Futur, Fondation Alzheimer, Programme Hospitalier de Recherche Clinique, Région Normandie, Association France Alzheimer et maladies apparentées, and Fondation Vaincre Alzheimer. CET reports research support from European Commission (Marie Curie International Training Network, JPND), Health Holland, the Dutch Research Council (ZonMw), The Weston Brain Institute, and Alzheimer Nederland; and has the following industrial collaborations: collaboration contract with ADx Neurosciences, contract research or received grants from Probiodrug, AC Immune, Biogen-Esai, CogRx, Toyama, Janssen Prevention Center, Boehringer, AxonNeurosciences, Fujirebio, EIP farma, PeopleBio, and Roche, and is on the advisory board of Roche. JC has provided consultation to Acadia, Actinogen, AgeneBio, Alkahest, Alzheon, Annovis, Avanir, Axsome, Biogen, Cassava, Cerecin, Cerevel, Cognoptix, Cortexyme, EIP Pharma, Eisai, Foresight, GemVax, Green Valley, Grifols, Hisun, Karuna, Nutricia, Orion, Otsuka, ReMYND, Resverlogix, Roche, Samumed, Samus Therapeutics, Third Rock, Signant Health, Sunovion, Suven, and United Neuroscience pharmaceutical and assessment companies. JC receives support from Keep Memory Alive, COBRE grant #P20GM109025, TRC-PAD #R01AG053798, and DIAGNOSE CTE #U01NS093334. JC owns the copyright of the Neuropsychiatric Inventory. WMVdF reports research support from ZonMw, NWO, EU-FP7, EU-JPND, Alzheimer Nederland, CardioVascular Onderzoek Nederland, Health∼Holland, Topsector Life Sciences & Health, Stichting Dioraphte, Gieskes-Strijbis Fonds, Stichting Equilibrio, Pasman Stichting, Fujifilm, Boehringer Ingelheim, Life-MI, AVID, Janssen Stellar, Combinostics. WMVdF is chair of Pasman Stichting. WMVdF has performed contract research for Biogen and received speaker fees from Biogen and Roche. Funding Information: Research at the Alzheimer Center Amsterdam is part of the neurodegeneration research programme of Amsterdam Neuroscience. The Alzheimer Centre Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc Fonds. The chair of Wiesje van der Flier is supported by the Pasman Stichting. MK and PS are recipients of the JPND-funded Euro-FINGERS project ( #ZonMW 733051102 ). Publisher Copyright: © 2021 Elsevier Ltd Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/4/24
Y1 - 2021/4/24
N2 - In this Seminar, we highlight the main developments in the field of Alzheimer's disease. The most recent data indicate that, by 2050, the prevalence of dementia will double in Europe and triple worldwide, and that estimate is 3 times higher when based on a biological (rather than clinical) definition of Alzheimer's disease. The earliest phase of Alzheimer's disease (cellular phase) happens in parallel with accumulating amyloid β, inducing the spread of tau pathology. The risk of Alzheimer's disease is 60–80% dependent on heritable factors, with more than 40 Alzheimer's disease-associated genetic risk loci already identified, of which the APOE alleles have the strongest association with the disease. Novel biomarkers include PET scans and plasma assays for amyloid β and phosphorylated tau, which show great promise for clinical and research use. Multidomain lifestyle-based prevention trials suggest cognitive benefits in participants with increased risk of dementia. Lifestyle factors do not directly affect Alzheimer's disease pathology, but can still contribute to a positive outcome in individuals with Alzheimer's disease. Promising pharmacological treatments are poised at advanced stages of clinical trials and include anti-amyloid β, anti-tau, and anti-inflammatory strategies.
AB - In this Seminar, we highlight the main developments in the field of Alzheimer's disease. The most recent data indicate that, by 2050, the prevalence of dementia will double in Europe and triple worldwide, and that estimate is 3 times higher when based on a biological (rather than clinical) definition of Alzheimer's disease. The earliest phase of Alzheimer's disease (cellular phase) happens in parallel with accumulating amyloid β, inducing the spread of tau pathology. The risk of Alzheimer's disease is 60–80% dependent on heritable factors, with more than 40 Alzheimer's disease-associated genetic risk loci already identified, of which the APOE alleles have the strongest association with the disease. Novel biomarkers include PET scans and plasma assays for amyloid β and phosphorylated tau, which show great promise for clinical and research use. Multidomain lifestyle-based prevention trials suggest cognitive benefits in participants with increased risk of dementia. Lifestyle factors do not directly affect Alzheimer's disease pathology, but can still contribute to a positive outcome in individuals with Alzheimer's disease. Promising pharmacological treatments are poised at advanced stages of clinical trials and include anti-amyloid β, anti-tau, and anti-inflammatory strategies.
UR - http://www.scopus.com/inward/record.url?scp=85104729158&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/S0140-6736(20)32205-4
DO - https://doi.org/10.1016/S0140-6736(20)32205-4
M3 - Review article
C2 - 33667416
SN - 0140-6736
VL - 397
SP - 1577
EP - 1590
JO - The Lancet
JF - The Lancet
IS - 10284
ER -